2024
Biologics for Psoriasis
Wride A, Chen G, Spaulding S, Tkachenko E, Cohen J. Biologics for Psoriasis. Dermatologic Clinics 2024, 42: 339-355. PMID: 38796266, DOI: 10.1016/j.det.2024.02.001.Peer-Reviewed Original ResearchConceptsIL-23IL-17ALong-term risk-benefit profileTNF-aLong-term adverse eventsIL-23 inhibitorsTumor necrosis factor-alphaP19 subunit of IL-23Risk-benefit profileSubunit of IL-23TNF-a inhibitorsTreatment of psoriasisNecrosis factor-alphaHigher Psoriasis AreaRates of short-termIL-12/23Psoriasis AreaIL-17FAdverse eventsIL-12IL-17Factor-alphaP19 subunitInjectable biologicsP40 subunit
2021
Dupilumab‐induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin‐17A expression: a case report
Mirza F, Wang A, Ramachandran S, Damsky W, Cohen J. Dupilumab‐induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin‐17A expression: a case report. British Journal Of Dermatology 2021, 185: 432-434. PMID: 33730377, DOI: 10.1111/bjd.20064.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, Monoclonal, HumanizedDermatitis, AtopicHumansInterleukin-17PhenotypePsoriasisConceptsInterleukin-17A expression